Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial

• Published in: PloS one Vol. 7; no. 2; p. e29341
• Main Authors: Carmeli, Cristian, Knyazeva, Maria G., Cuénod, Michel, Do, Kim Q.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 22.02.2012; Public Library of Science (PLoS)
• Subjects: Acetylcysteine; Acetylcysteine - pharmacology; Adult; Antipsychotics; Biology; Biomarkers; Clinical trials; Cross-Over Studies; Cysteine; Cystine; Double-Blind Method; Double-blind studies; EEG; Electroencephalography - methods; Female; Free Radical Scavengers - pharmacology; Glutathione; Glutathione - metabolism; Head; Humans; Male; Medicine; Mental disorders; Models, Statistical; Multivariate Analysis; Neuropathology; Neurophysiology; Neurosciences; Oscillometry; Oxidation-Reduction; Oxidative stress; Patients; Placebos; Precursors; Psychiatry; Psychotropic drugs; Randomization; Rhythm; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - physiopathology; Signal Processing, Computer-Assisted; Social and Behavioral Sciences; Synchronism; Synchronization; Thiols; United States > US; Switzerland
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0029341

Glutathione (GSH) dysregulation at the gene, protein, and functional levels has been observed in schizophrenia patients. Together with disease-like anomalies in GSH deficit experimental models, it suggests that such redox dysregulation can play a critical role in altering neural connectivity and synchronization, and thus possibly causing schizophrenia symptoms. To determine whether increased GSH levels would modulate EEG synchronization, N-acetyl-cysteine (NAC), a glutathione precursor, was administered to patients in a randomized, double-blind, crossover protocol for 60 days, followed by placebo for another 60 days (or vice versa). We analyzed whole-head topography of the multivariate phase synchronization (MPS) for 128-channel resting-state EEGs that were recorded at the onset, at the point of crossover, and at the end of the protocol. In this proof of concept study, the treatment with NAC significantly increased MPS compared to placebo over the left parieto-temporal, the right temporal, and the bilateral prefrontal regions. These changes were robust both at the group and at the individual level. Although MPS increase was observed in the absence of clinical improvement at a group level, it correlated with individual change estimated by Liddle's disorganization scale. Therefore, significant changes in EEG synchronization induced by NAC administration may precede clinically detectable improvement, highlighting its possible utility as a biomarker of treatment efficacy. ClinicalTrials.gov NCT01506765.